<DOC>
	<DOCNO>NCT02590250</DOCNO>
	<brief_summary>This Post-Marketing Surveillance study India evaluate safety efficacy BOTOX® ( Botulinum Toxin Type A ) treatment patient urinary incontinence due neurogenic detrusor overactivity overactive bladder .</brief_summary>
	<brief_title>A Safety Efficacy Study BOTOX® ( Botulinum Toxin Type A ) Patients With Urinary Incontinence Due Neurogenic Detrusor Overactivity Overactive Bladder India</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients urinary incontinence due NDO OAB treat BOTOX® per local standard care clinical practice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>